The intestinal microbial metabolite desaminotyrosine is an anti‐inflammatory molecule that modulates local and systemic immune homeostasis. Issue 12 (13th October 2020)

• Record Type: Journal Article
• Authors: Wei, Yanxia; Gao, Jing; Kou, Yanbo; Liu, Mengnan; Meng, Liyuan; Zheng, Xingping; Xu, Shihong; Liang, Ming; Sun, Hongxiang; Liu, Zhuanzhuan; Wang, Yugang
• Is Part Of: FASEB journal. Volume 34:Issue 12(2020)
• Page Start: 16117
• Page End: 16128
• Publication Date: 2020-10-13
• Subjects: desaminotyrosine -- flavonoids -- microbial metabolite -- mucosal barrier -- type I IFN; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201902900RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: It is considered that intestinal barrier dysfunction and systemic endotoxemia drive obesity and its related complications. However, what causes barrier dysfunction remains to be elucidated. Here, we showed that the gut microbiota from high‐fat diet (HFD)‐fed mice had impaired ability to degrade dietary flavonoids, and in correspondence, the microbial‐derived flavonoid metabolite desaminotyrosine (DAT) was reduced. Supplementation of DAT in the drinking water was able to counter the HFD‐induced body fat mass accumulation and body weight increment. This is correlated with the role of DAT in maintaining mucosal immune homeostasis to protect barrier integrity. DAT could attenuate dextran sodium sulfate (DSS)‐induced mucosal inflammation in a type I interferon signal‐dependent manner. Furthermore, intraperitoneal injection of DAT‐protected mice from bacterial endotoxin‐induced septic shock. Together, we identified DAT as a gut microbiota‐derived anti‐inflammatory metabolite that functions to modulate local and systemic immune homeostasis. Our data support the notion of dysbiosis being an important driving force of mucosal barrier dysfunction and systemic metabolic complications.